September 3, 2024 09:43 PM EDT

Athira’s small molecule drug for Alzheimer’s fails in mid-stage study

Ryan Cross

Senior Science Correspondent

A daily injection intended to protect and regenerate brain cells has failed to slow the progression of Alzheimer’s disease in a Phase 2/3 clinical trial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Athira’s small molecule drug for Alzheimer’s fails in mid-stage study

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Charles River to close ‘15 smaller sites’ as demand for early research declines

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Athira gives up on lead Alzheimer’s drug, switches tack to ALS

Nkarta drops another cancer program as it leans into autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Athi­ra’s small mol­e­cule drug for Alzheimer’s fails in mid-stage study

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Charles Riv­er to close ‘15 small­er sites’ as de­mand for ear­ly re­search de­clines

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Athi­ra gives up on lead Alzheimer’s drug, switch­es tack to ALS

Nkar­ta drops an­oth­er can­cer pro­gram as it leans in­to au­toim­mune dis­ease

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Athira’s small molecule drug for Alzheimer’s fails in mid-stage study

Charles River to close ‘15 smaller sites’ as demand for early research declines

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Athira gives up on lead Alzheimer’s drug, switches tack to ALS

Nkarta drops another cancer program as it leans into autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks